RPRX · Royalty Pharma plc

conf 2/10 partial

enthusiasm:21.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:0 · business_impact:4 · disruption:0 · commitment:-4 · confirmation:3

Enthusiasm latest 7 / prev 1 (rising)

AI surfaced only in Q1 FY2026: management frames it as the next layer on a long-standing data moat (claims + EMR analytics) that already improved deal selection and partner terms (Voranigo case study), not as a new revenue line. Credibility is moderate—the data assets and one named outcome are concrete, but there is no quantified AI impact on deals, costs, or margins, and the Head of AI hire signals most benefits are still forward-looking (automated diligence, scaled analytics).

Grounded on actual base — revenue $2.4B · net income $0.8B · net margin 32.4% · diluted EPS 1.8

These are next-fiscal-year annual uplift estimates, not next-quarter numbers.

Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: medium (model's call-read: high; verdict above is the hard-data one used for ranking) · confidence: 2/10

Assumptions: FY base: revenue $2,378,193,000; GAAP net income $770,947,000; GAAP diluted EPS $1.80; shares 559,611,000. Default incr. net margin 32.4% (=770,947/2,378,193) and tax 21% never applied because no claim carries a dollar revenue or cost figure to flow. EPS sizing uses the consensus ADJUSTED basis (~$2.53B FY25 adj. net income / 559.6M sh ≈ $4.5 adj. EPS), NOT the $770.9M GAAP figure, which would inflate any EPS% ~3.3×. Phasing N/A — no timed $ AI target. All claims adopter-side (AI improves RPRX's own diligence/underwriting); zero supplier-side AI revenue.

Top line: No quantifiable topline AI uplift. Management's only numbers are data-asset scale (200M claims lives, 44M EMR lives, 9 yrs history) and a single Voranigo anecdote (1,500 diagnosed, 15,000 warehoused). None is a revenue claim; converting patient counts to RPRX revenue would require an undisclosed drug price, royalty rate and penetration — so no rev_uplift_pct is computable without inventing. The data edge plausibly improves which royalties RPRX buys, but that shows up inside the existing royalty-acquisition revenue line, not as separable AI revenue.

Bottom line: AI here is a diligence/underwriting productivity tool (new Head of AI Lucas Glass, 'automating all diligence processes'), but management attached no FTE count, no opex-savings dollar, and no productivity percentage — so no after-tax saving and no EPS% can be derived. The EPS denominator must be the adjusted ~$2.53B net income; the $770.9M GAAP figure would have turned even a tiny saving into a misleadingly large EPS%.

[impact n/m (all claims soft/unanchored)] Adopter-side math sums to null rev and null EPS uplift (no hard $ claims). Consensus already embeds strong growth driven by royalty-portfolio acquisitions, not a separately quantified AI line: revenue $2,378M → ~$3,453M FY26 → $3,711M FY27 (+7.5% y/y); adj. EPS ~$4.5 base → $5.13 FY26 → $5.62 FY27 vs GAAP $1.80. Because management disclosed zero dollar/percentage AI impact, there is no aggregate AI increment to compare against this curve — AI contribution is folded into (and indistinguishable from) the underwriting that already produces consensus growth, so there is no evidence the Street is behind on AI specifically.

• Royalty Pharma has been making significant investments in data for many years, decades.
• We have about 200 million people's claims data for 200 million Americans.
• We have electronic medical records for 44 million Americans and about 9 years of longitudinal data.
• And in some cases, that has led to better terms on transactions.
• One of those is, for example, Voranigo, where we realized when we made that investment that in that form of cancer, there were about 1,500 patients being diagnosed each year. But on the sidelines, about 15,000 patients that were not recurring to treatment because the options were not attractive, drugs that were toxic safety issues and not that effective.
• And that -- as a result of that, we were able to forecast a much stronger launch for Voranigo than I think anybody was seeing and then higher peak sales.

• In the first quarter, we also took major steps to strengthen our global platform and capabilities in partnering the Asia Pacific region and artificial intelligence.
• We have brought in exceptional new leaders to our team with Greg Butz, Ken Sun and Lucas Glass.
• And the way we use this is for our own internal purposes to make better investments, understand better what's going on with the products and how we forecast them.
• But one of the very exciting things for Royalty Pharma is to actually use data with our partners and share insights that we gain as we do our analysis and as we follow the ecosystem.
• And we think that is a differentiating aspect that is important to us because we don't see ourselves like others as purely capital providers but we see ourselves as partners with the companies that we're partnering with, where we can provide -- we add value by sharing data and insights with them, and they appreciate that.
• when we look into our claims data is a really rapidly growing part of this market is patients who have been treated through multiple lines.

• we're very fortunate recently to have hired Lucas Glass as Head of AI for Royalty Pharma.
• And he's going to be responsible for developing and implementing AI capabilities across our business including automating all of our diligence processes and strengthening how we evaluate and invest in royalties and also support our partners.
• So we're very excited about where we can take the business now with Lucas and the team that we're building in addition to the team that we already had.

—/100 (no quantified promises)   no-quantified-promises  6 calls reviewed

Across six earnings calls (Q4 FY2024–Q1 FY2026), management never stated a quantified AI/ML/automation target with a number and deadline—only generic references such as proprietary analytics on deals and, in Q1 FY2026, hiring AI leadership without measurable goals. There is no AI promise-versus-delivery track record to score.

Est. revisions rising  ·  Fwd P/E 11.7  ·  EV/Sales 13.0x

AI claim maps to Financial Royalty Assets, Royalty Income, Other

AI enthusiasm across 6 calls — trend ↗ rising

Five calls offered only vague proprietary analytics; Q1 2026 first explicit AI platform hires with no concrete use cases yet.

• 2026-03-23 · Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

5/10 qualitative impact   moderate  medium-term · soft evidence

Where AI matters: royalty underwriting & partner analytics

Claims/EMR data already inform deal selection and partner terms (e.g., Voranigo), but the new AI layer is mostly forward-looking—Head of AI hire and diligence automation—with no disclosed revenue, margin, or productivity impact.

Caveats: Upside may reflect legacy data analytics rather than new AI with no separated P&L proof; Competitors or sponsors could replicate similar RWD/ML tools and narrow sourcing edge; Management declined to quantify deal-win rates, spreads, or diligence efficiency gains

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 2/10

RPRX earns contractual royalties on drug sales; AI does not replace that revenue stream or deflate billable labor in the core model, and may modestly sharpen underwriting versus less data-rich capital providers.

option liquidity: fair

proxy inputs — dollar-ADV $193M · beta 0.396 · px $54.21

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.